Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease
- 1 February 2002
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 105 (4) , 285-290
- https://doi.org/10.1016/s0049-3848(02)00034-8
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Statins do more than just lower cholesterolThe Lancet, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol LevelsCirculation, 1995
- Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina PectorisNew England Journal of Medicine, 1995
- Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up.Circulation, 1993
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- HYPERTRIGLYCERIDAEMIA AND HYPERCOAGULABILITYThe Lancet, 1983